TNFRSF4 and neoplasm: Immune monitoring using flow cytometry, quantitative multiplex immunochemistry (mIHC), and TCR sequencing to interrogate the effects of anti-OX40 in the tumor, suggests that increases in the tumor-reactive CD8+ TIL population may serve as a biomarker of clinical activity.